However, clinical trials evaluating the effects of pharmacologic agents—such as GLP-1 receptor agonists and SGLT2 inhibitors—on liver fat and fibrosis in T1D would be valuable. The gene discussed is GLP1R; the disease is type 1 diabetes mellitus.